Metastatic Colorectal Cancer: Prognostic and Predictive Factors

被引:16
作者
Nappi, Anna [1 ]
Nasti, Guglielmo [2 ]
Romano, Carmela [1 ]
Berretta, Assimiliano [3 ]
Ottaiano, Alessandro [2 ]
机构
[1] Ist Nazl Tumori Napoli, IRCCS G Pascale, Natl Canc Inst, Abdominal Med Oncol, Naples, Italy
[2] Ist Nazl Tumori Napoli, IRCCS G Pascale, SSD Innovat Therapies Abdominal Metastases, Naples, Italy
[3] Natl Canc Inst CRO, Dept Med Oncol, Aviano, PN, Italy
关键词
Colorectal cancer; metastases; prognostic factors; predictive factors; biologic therapy; chemotherapy; KRAS WILD-TYPE; TUMOR MUTATIONAL BURDEN; GROWTH-FACTOR RECEPTOR; BODY-MASS INDEX; 1ST-LINE TREATMENT; MICROSATELLITE INSTABILITY; COLON-CANCER; ACQUIRED-RESISTANCE; PTEN EXPRESSION; MSI-H;
D O I
10.2174/0929867326666190620110732
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer represents the third most frequently occurring cancer worldwide. In the last decade, the survival of patients affected by metastatic colorectal cancer (mCRC) has improved through the introduction of biological drugs. However, in this new and dynamic therapeutic context, research about prognostic and predictive factors is important to guide the oncologists to effective therapies as well as to improve the understanding of colorectal cancer biology. Their identification is an intensive area of research and our future goal will be to depict tumour-specific "molecular signatures" in order to predict the clinical course of the disease and the best treatments. In this report, we describe clinical, pathological and molecular biomarkers that can play a role as prognostic or predictive factors in mCRC.
引用
收藏
页码:2779 / 2791
页数:13
相关论文
共 82 条
[41]   HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients [J].
Martin, V. ;
Landi, L. ;
Molinari, F. ;
Fountzilas, G. ;
Geva, R. ;
Riva, A. ;
Saletti, P. ;
De Dosso, S. ;
Spitale, A. ;
Tejpar, S. ;
Kalogeras, K. T. ;
Mazzucchelli, L. ;
Frattini, M. ;
Cappuzzo, F. .
BRITISH JOURNAL OF CANCER, 2013, 108 (03) :668-675
[42]   Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J].
Maughan, Timothy S. ;
Adams, Richard A. ;
Smith, Christopher G. ;
Meade, Angela M. ;
Seymour, Matthew T. ;
Wilson, Richard H. ;
Idziaszczyk, Shelley ;
Harris, Rebecca ;
Fisher, David ;
Kenny, Sarah L. ;
Kay, Edward ;
Mitchell, Jenna K. ;
Madi, Ayman ;
Jasani, Bharat ;
James, Michelle D. ;
Bridgewater, John ;
Kennedy, M. John ;
Claes, Bart ;
Lambrechts, Diether ;
Kaplan, Richard ;
Cheadle, Jeremy P. .
LANCET, 2011, 377 (9783) :2103-2114
[43]   Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer [J].
Misale, Sandra ;
Yaeger, Rona ;
Hobor, Sebastijan ;
Scala, Elisa ;
Janakiraman, Manickam ;
Liska, David ;
Valtorta, Emanuele ;
Schiavo, Roberta ;
Buscarino, Michela ;
Siravegna, Giulia ;
Bencardino, Katia ;
Cercek, Andrea ;
Chen, Chin-Tung ;
Veronese, Silvio ;
Zanon, Carlo ;
Sartore-Bianchi, Andrea ;
Gambacorta, Marcello ;
Gallicchio, Margherita ;
Vakiani, Efsevia ;
Boscaro, Valentina ;
Medico, Enzo ;
Weiser, Martin ;
Siena, Salvatore ;
Di Nicolantonio, Federica ;
Solit, David ;
Bardelli, Alberto .
NATURE, 2012, 486 (7404) :532-U131
[44]   Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis [J].
Modest, Dominik Paul ;
Reinacher-Schick, Anke ;
Stintzing, Sebastian ;
Giessen, Clemens ;
Tannapfel, Andrea ;
Laubender, Ruediger Paul ;
Brodowicz, Thomas ;
Knittelfelder, Regina ;
Vrbanec, Damir ;
Schmiegel, Wolff ;
Heinemann, Volker ;
Zielinski, Christoph C. .
ANTI-CANCER DRUGS, 2012, 23 (06) :666-673
[45]   Association of CTNNB1 (β-Catenin) Alterations, Body Mass Index, and Physical Activity With Survival in Patients With Colorectal Cancer [J].
Morikawa, Teppei ;
Kuchiba, Aya ;
Yamauchi, Mai ;
Meyerhardt, Jeffrey A. ;
Shima, Kaori ;
Nosho, Katsuhiko ;
Chan, Andrew T. ;
Giovannucci, Edward ;
Fuchs, Charles S. ;
Ogino, Shuji .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (16) :1685-1694
[46]   Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives [J].
Nappi, Anna ;
Berretta, Massimiliano ;
Romano, Carmela ;
Tafuto, Salvatore ;
Cassata, Antonino ;
Casaretti, Rossana ;
Silvestro, Lucrezia ;
De Divitiis, Chiara ;
Alessandrini, Lara ;
Fiorica, Francesco ;
Ottaiano, Alessandro ;
Nasti, Guglielmo .
CURRENT CANCER DRUG TARGETS, 2018, 18 (05) :421-429
[47]   CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies [J].
Ogino, S. ;
Cantor, M. ;
Kawasaki, T. ;
Brahmandam, M. ;
Kirkner, G. J. ;
Weisenberger, D. J. ;
Campan, M. ;
Laird, P. W. ;
Loda, M. ;
Fuchs, C. S. .
GUT, 2006, 55 (07) :1000-1006
[48]   Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology [J].
Ogino, S. ;
Lochhead, P. ;
Giovannucci, E. ;
Meyerhardt, J. A. ;
Fuchs, C. S. ;
Chan, A. T. .
ONCOGENE, 2014, 33 (23) :2949-2955
[49]   Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology [J].
Ogino, Shuji ;
Nowak, Jonathan A. ;
Hamada, Tsuyoshi ;
Milner, Danny A., Jr. ;
Nishihara, Reiko .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 14, 2019, 14 :83-103
[50]   Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine [J].
Ogino, Shuji ;
Nowak, Jonathan A. ;
Hamada, Tsuyoshi ;
Phipps, Amanda I. ;
Peters, Ulrike ;
Milner, Danny A., Jr. ;
Giovannucci, Edward L. ;
Nishihara, Reiko ;
Giannakis, Marios ;
Garrett, Wendy S. ;
Song, Mingyang .
GUT, 2018, 67 (06) :1168-1180